Udenafil: Phase I/II started

Mezzion began an open-label, dose-escalation, U.S. Phase I/II trial to evaluate 35.7 and 87.5 mg udenafil given once or twice daily and 125 mg udenafil given once daily for 5 days in about 36 adolesce...